Maxcyte Share Discussion Threads

[someuwin] 04/2/2021 09:38

Amazing business model. License payments. Equipment sales. Recurring lease payments. Consumables payments. Milestone payments. Consultation payments. Plus, the holy grail of future royalties on successful product launches from their multiple big pharma partners.

[adamb1978] 04/2/2021 09:24

I think the money raised is just a bridge to raise investor awareness and appetite. Its only a small $ amount which has been raised and I'd imagine these investors will be looking for a large value holding, and are therefore going to be buyers post-Nasdaq listing. The balance sheet strength will also show that the company has the firepower to be able to accelerate growth once on Nasdaq, and therefore draw in more investors

[nimbo1] 04/2/2021 09:19

Perhaps they raised the money to strengthen shareholder base so they can keep would be acquirers at bay

[someuwin] 04/2/2021 09:17

They're going to go crazy for this stock when it lists on NASDAQ later this year.

[trident5] 04/2/2021 08:47

N1 - from memory you compared it to a fridge maker and I compared your fridge maker to AO, who are more a fridge retailer to be fair, but your linkage seemed more tenuous.

[someuwin] 04/2/2021 08:44

Amazing potential future royalties on success with any of these growing number of partner clinical trials...

[assagai] 04/2/2021 08:41

I see trident has been popping up and I can imagine the nature of his posts. Major case of sour grapes/fomo I imagine. I filtered him a couple of years ago from another thread.

[multibagger] 04/2/2021 08:40

A few double digit trades coming through - looks like a "Popular Investor/guru" has taken this to his/her "copy trades". Though not hugely mainstream as yet, the sheer volumes that these hordes of copy traders can trigger can be astounding. Not to be underestimated. Not completely dissimilar in structure to the GME saga...in some ways. Edit: I think we'll close £8+ today of the above pans out !

[multibagger] 04/2/2021 08:22

Great to see the share price ascending - validating what many of us thought would happen ! Time to nuke the Trident I think from responses on this board - I nuked/filtered a long time ago to save myself the drivel.

[nimbo1] 04/2/2021 08:17

I could go back and highlight plenty of remarks about 'ramping' when the price was closer to £4.50 and I said it could be a £1 bil co. You compared it to AO World FFS. Anyway no need to clog the board with this. Congrats all holders and GL - this has flown now, time to sit back and see where insti's want to value it - D1 investment puts it on the radar of all major US healthcare investors...they have a big following in the US.

[trident5] 04/2/2021 08:13

What's snarky about highlighting the director sale and then asking a question about it?

[nimbo1] 04/2/2021 08:09

Congrats trident - why the stream of snarky posts then? Doesn't befit a long term holder. Its getting on for a 6x for me from my initial 1.15 buy. My average is much higher though as have averaged up with volume...but who's counting up here!

[someuwin] 04/2/2021 08:02

Good start.

[trident5] 04/2/2021 08:01

74 - it was a question - so not wrong. N1 - price up 3x since I bought, fella.

[nimbo1] 04/2/2021 07:52

trident is intellectually challenged - price up about 60% since he started posting...I say long may it continue. 5 mm's at £7...

[74tom] 04/2/2021 07:47

Yes... you feeling a bit stupid yet Trident? You’ve been completely & utterly wrong on this one, a tragic comedy!

[trident5] 04/2/2021 07:42

When they issued their RNS after markets closed last night it said the directors were going to exercise their options with an intention to sell the shares. This morning before markets opened the RNS said they have been sold. Are they able to sell these off the market?

[assagai] 03/2/2021 22:54

Spot on I think. There dont appear to be any negatives in selling by insiders if you study the subtleties! Be interesting to see if we reset to £7 at the off in the morning.... As a starting point!...

[acuere] 03/2/2021 22:20

“Proceeds from the Subscription will be used to strengthen MaxCyte's balance sheet to enable the Company to support the burgeoning field of next-generation cell therapeutic development via its best-in-class cell engineering approaches.” “........the Subscription, which was significantly over-subscribed, ........ have indicated their intention to exercise up to 755,000 options over new Common Stock in total and to sell such new Common Stock to help satisfy unfulfilled demand” Institutions want in now, and it’s deemed worth keeping them happy to ensure successful Nasdaq listing later this year.

[2theduke] 03/2/2021 20:46

It’s for liquidity in the shares pre us listing. In a nutshell

[nimbo1] 03/2/2021 20:31

I have no idea!

[trickydicky1] 03/2/2021 20:24

I think I’ll ask the question again. What’s it for? Unless the answer is NASDAQ listing fees, but $45m sounds rather a lot (they already have $40m on the balance sheet). What might they be looking to buy?

[nimbo1] 03/2/2021 19:40

Most important thing other than price is investment by d1 - one of the best investors in the US. Very highly thought of with lots of aum, they’ll be buying more on Nasdaq :)

[2theduke] 03/2/2021 18:57

It’s definitely at good idea to note the director sale, albeit it’s the (much) smaller part of the story and action. Also note the recent placement they’ve had for employee incentives. As such they still have plenty of skin in the game. As previously noted they took their first ever options out just this year at c £3.5 or so off the top of my head, that’s after a decade+ of hard graft. I’m not sure their that focused on the money Vs creating viable medicine.

[trident5] 03/2/2021 18:18

N1 - You shouldn't be annoyed at the truth and clog your brain with your biases - I'm only pointing out what was also in today's RNS to enable a more balanced view. Just trumpeting the good news is a crowded stage on bulletin boards. Insiders selling £5m, whilst outsiders buying £40m, is noteworthy - I didn't see anyone else on here pointing it out.